Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Part 3 Specific Therapeutic Areas
- Chapter 17 Psychotropic Drug Treatment in Childhood and Adolescence
- Chapter 18 Psychotropic Drug Treatment in Later Life
- Chapter 19 Psychotropic Prescribing in Pregnancy and Lactation
- Chapter 20 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation
- Chapter 21 Antipsychotics, Weight Gain and Metabolic Risk
- Index
- References
Chapter 19 - Psychotropic Prescribing in Pregnancy and Lactation
from Part 3 - Specific Therapeutic Areas
Published online by Cambridge University Press: 29 May 2020
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Part 3 Specific Therapeutic Areas
- Chapter 17 Psychotropic Drug Treatment in Childhood and Adolescence
- Chapter 18 Psychotropic Drug Treatment in Later Life
- Chapter 19 Psychotropic Prescribing in Pregnancy and Lactation
- Chapter 20 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation
- Chapter 21 Antipsychotics, Weight Gain and Metabolic Risk
- Index
- References
Summary
The decision to prescribe psychotropic medication is always a matter of weighing up potential risks and benefits but at no time is this more difficult than in pregnancy and the post-partum period. This is because the risks do not only relate to the side-effects for the mother but also potential adverse outcomes for the pregnancy and the child who may be particularly vulnerable during fetal development and breastfeeding. In addition, there is often a degree of uncertainty about what added risks medication may bring compared with no treatment.
- Type
- Chapter
- Information
- Seminars in Clinical Psychopharmacology , pp. 577 - 598Publisher: Cambridge University PressPrint publication year: 2020